Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Second Quarter 2019 Financial Results

TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
July 24, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Corporate Update

FDA meeting scheduled to discuss the pivotal path for intratumoral TTI-621 in CTCLIntravenous TTI-621 protocol amended to enable dosing beyond 0.5 mg/kg and first patient cohort enrollingEnrollment in...
July 02, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
May 13, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports First Quarter 2019 Financial Results

TORONTO, May 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
April 30, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Management and Board Changes and Provides Corporate Update

TORONTO, April 30, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
April 15, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients

TORONTO, April 15, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
April 11, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

TORONTO, April 11, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
April 08, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Present at Investor Conferences in April

TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
April 02, 2019 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program

TORONTO, April 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
March 27, 2019 17:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019

TORONTO, March 27, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...